2:44 PM
 | 
Oct 10, 2018
 |  BC Extra  |  Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program.

The prices will go into effect by the end of October and will remain valid until Nov. 30, 2020. The list includes dosage and pricing information; according to the document, the percentage paid by insurance is determined by each local coordinating area.

In August, China announced that it would begin insurance access and reimbursement negotiations of 18 cancer drugs, and Wednesday's list includes all but one of those (see "China Unveils Cancer Drugs for Medical Insurance Access Negotiation").

Included in the list are Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG), BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and Pfizer Inc. (NYSE:PFE) for myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia and acute myelogenous leukemia (AML); Stivarga regorafenib from Bayer AG (Xetra:BAYN) and Amgen Inc. (NASDAQ:AMGN) for hepatocellular carcinoma (HCC), colorectal cancer (CRC) and gastrointestinal stromal tumors (GIST); Erbitux cetuximab from Eli Lilly and Co. (NYSE:LLY) and Merck KGaA (Xetra:MRK) for CRC; and Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV) for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The drug on August's list omitted on Wednesday is myelofibrosis drug Jakavi ruxolitinib from Incyte Corp. (NASDAQ:INCY) and Novartis AG (NYSE:NVS; SIX:NOVN).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD